Cytodyn Inc (CYDY)

[finesand]

we already posted the paper (o8>

See https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140958341

Important, this is about Trial CD01 and its extension study,
not pivotal CD02 Combo or CD03 Mono.

However, one big cookie posted in paper and news was

Of the 18 patients considered non-responders, all achieved re-suppressed viral load upon resuming their prior ART regimen

because this is one important secondary endpoint for CD02 and CD03.

Timing and strategy of PR'ing the April 2018 paper is up to you, but I agree that they previously probably had a different strategy.

BTW .. if those phone calls are genuine, re your share count etc, one could almost derive a tender offer for your shares ..